High-Dose Radiation Therapy Questioned in Localized Prostate Cancer

High-Dose Radiation Therapy Questioned in Localized Prostate Cancer
shutterstock_157146146The latest results from the Radiation Therapy Oncology Group (RTOG) 0126 clinical trial studying the effect of radiation therapy (RT) dosage in the treatment of localized prostate cancer in the United States, were presented at the American Society for Radiation Oncology (ASTRO) 56th Annual Meeting. The study was conducted at 104 U.S. centers and compared high-dose radiation therapy (79.2 Gy), considered to be the standard of care for this group of patients, with standard-dose RT (70.2 Gy) in the treatment of more than 1,500 men with intermediate-risk prostate cancer, (T1b to T2b disease), with Gleason scores ranging from 2 to 7 and prostate-specific antigen (PSA) levels between 10 ng/mL and 20 ng/mL. All patients had negative lymph nodes and no metastases and none had received previous hormone therapy. One-third of men in the trial received intensity-modulated radiation therapy (IMRT) and two-thirds received 3-dimensional conformal radiation therapy (3D-CRT). At a follow up of 10 years, no significant difference in overall survival was observed between the two groups, with 66.7% vs 65.6% i
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *